Met Life Investment Management, LLC Protagonist Therapeutics, Inc Transaction History
Met Life Investment Management, LLC
- $17.1 Billion
- Q3 2024
A detailed history of Met Life Investment Management, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Met Life Investment Management, LLC holds 33,805 shares of PTGX stock, worth $1.38 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
33,805
Previous 33,805
-0.0%
Holding current value
$1.38 Million
Previous $1.17 Million
29.72%
% of portfolio
0.01%
Previous 0.01%
Shares
30 transactions
Others Institutions Holding PTGX
# of Institutions
247Shares Held
56.4MCall Options Held
76.3KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$238 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$234 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$221 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$172 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$130 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...